SAN DIEGO, CA -- Aug. 03, 2022 -- InvestorsHub NewsWire
-- Sigyn Therapeutics, Inc. (OTCQB:
SIGY), a development-stage medical technology company focused
on addressing unmet needs in global health, announces that its
securities will commence trading on the OTCQB® Venture Exchange at
the open of today’s market. The Company’s securities, which
previously traded on the OTC Pink Market, will continue to trade
under the ticker symbol "SIGY".
To address unmet needs in global health, the Company is
advancing Sigyn Therapy™, a broad-spectrum blood purification
technology that extracts infectious viruses, bacterial toxins, and
life-threatening inflammatory mediators from the bloodstream.
Candidate treatment opportunities include sepsis (leading cause of
hospital deaths), community acquired pneumonia (a leading cause of
infectious disease deaths), emerging pandemic threats, and
end-stage renal disease (ESRD) inflammation and
endotoxemia.
“In parallel with our advancement of Sigyn Therapy, the
graduation of our securities to the OTCQB is a natural evolution in
our pursuit to list on a major exchange,” stated Jim Joyce,
co-founder and CEO of Sigyn Therapeutics. “We thank the team at OTC
Markets Group for approving our application.”
Previously, Mr. Joyce (founder, former Chairman and CEO of
Aethlon Medical) oversaw the development of the Aethlon
Hemopurifier®, a broad-spectrum blood purification technology to
address life-threatening viruses. During Mr. Joyce’s tenure, the
Hemopurifier became the first therapeutic candidate to receive two
“Breakthrough Device” designations from the United States Food and
Drug Administration (FDA) and was named a “Top 25 Invention” and
one of the “11 Most Remarkable Advances in Healthcare” by TIME
magazine.
About
The OTCQB® Venture
Market
The OTCQB® Venture Market, operated by OTC Markets Group, is for
entrepreneurial and development stage U.S. and international
companies. To be eligible for OTCQB quotes, companies must be
current in their disclosure filings, have audited financial
statements, and undergo an annual validation and management
certification process. Companies must also meet minimum bid testing
and other financial terms. OTCQB is recognized as an established
public market by the Securities and Exchange Commission and
provides current public information to investors in need of
securities analysis, valuation, and trading.
About Sigyn Therapeutics™
Sigyn Therapeutics is a development-stage company focused on
addressing unmet needs in global health. Sigyn Therapy™ is a
broad-spectrum blood purification technology that extracts
infectious viruses, bacterial toxins, and life-threatening
inflammatory mediators from the bloodstream. Based on these
capabilities, candidate treatment indications for Sigyn Therapy
include pathogen-associated disorders that precipitate sepsis (a
leading cause of hospital deaths), community acquired pneumonia (a
leading cause of death among infectious diseases), emerging
pandemic threats, and inflammation & endotoxemia in dialysis
dependent end-stage renal disease (ESRD) patients. According to the
U.S. Renal Data System, approximately 550,000 individuals suffer
from ESRD in the United States.
To learn more, visit www.SigynTherapeutics.com
Cautionary Note Regarding Forward-Looking Statements
This information in this press release contains forward-looking
statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve
substantial risks and uncertainties. All statements contained in
this summary are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. These
forward-looking statements are based upon Sigyn's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such
differences may include, without limitation, the Company's ability
to clinically advance Sigyn Therapy in human studies required for
market clearance, the Company's ability to manufacture Sigyn
Therapy, the Company's ability to raise capital resources, and
other potential risks. The foregoing list of risks and
uncertainties is illustrative but is not exhaustive. Additional
factors that could cause results to differ materially from those
anticipated in forward-looking statements can be found under the
caption "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2021, and in the Company's other
filings with the Securities and Exchange Commission, including its
quarterly Reports on Form 10-Q. All forward-looking statements
contained in this report speak only as of the date on which they
were made. Except as may be required by law, the Company does not
intend, nor does it undertake any duty, to update this information
to reflect future events or circumstances.
Contacts:
Stephen Kilmer
Sigyn Therapeutics, Inc.
Investor Relations
(646) 274-3580
stephen@sigyntherapeutics.com
Sigyn Therapeutics (QB) (USOTC:SIGY)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Sigyn Therapeutics (QB) (USOTC:SIGY)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
